Study Evaluating the Safety, in Terms of HBV Virological Control at 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected With the HIV-1 and HBV Viruses

Conditions: HIV Infections; HBV Coinfection Interventions: Drug: TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI; Drug: Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR) Sponsors: ANRS, Emerging Infectious Diseases Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials